Meningeal carcinomatosis: CSF cytology, immunocytochemistry and biochemical tumor markers.
CSF cytology, immunocytochemistry and biochemical tumor markers were compared in 12 patients with a meningeal carcinomatosis regarding diagnostic significance and therapy control; 50 samples were investigated. Cytology was tumor-positive in 39 samples and immunocytochemistry in 45 samples. Intrathecally produced tumor markers were found in 47 samples. On initial examination only immunocytochemical testing correctly classified all cases. Cytology and biochemical tumor markers revealed positive results in 10 respectively 11 of 12 patients, combined use of these two methods would increase the sensitivity to 100%. On follow-up examination tumor markers correlated best with symptoms and were early indicators for clinical relapse. These results could be achieved only if several monoclonal antibodies and biochemical tumor marker tests were combined. It is concluded that immunocytochemistry and biochemical tumor markers are of major help regarding the problems of false-negative cytology and reliable therapy control in meningeal carcinomatosis.
Oschmann
P
P
Department of Neurology, University of Giessen, Germany.
Kaps
M
M
Völker
J
J
Dorndorf
W
W
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor; D002277:Carcinoma / Q000134:cerebrospinal fluid* / Q000473:pathology / Q000628:therapy; D002555:Cerebrospinal Fluid / Q000166:cytology*; D004358:Drug Therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008577:Meningeal Neoplasms / Q000134:cerebrospinal fluid* / Q000473:pathology; D008875:Middle Aged
D014408:Biomarkers, Tumor